Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500

BenzingaNov 1 03:23

Bernstein Maintains Outperform on Natera, Raises Price Target to $135

BenzingaOct 31 02:59 · Ratings

Natera Shares Are Trading Higher After Canaccord Genuity Maintained a Buy Rating on the Stock and Raised Its Price Target From $145 to $150.

BenzingaOct 30 01:41

Looking Into Intellia Therapeutics's Recent Short Interest

BenzingaOct 29 21:45

Baird Maintains Neutral on Intellia Therapeutics, Lowers Price Target to $18

BenzingaOct 25 20:23 · Ratings

Intellia Therapeutics Analyst Ratings

BenzingaOct 25 05:42 · Ratings